Published in J Virol on September 01, 2005
Evidence for HIV-associated B cell exhaustion in a dysfunctional memory B cell compartment in HIV-infected viremic individuals. J Exp Med (2008) 5.14
A group M consensus envelope glycoprotein induces antibodies that neutralize subsets of subtype B and C HIV-1 primary viruses. Virology (2006) 3.26
Selection on the human immunodeficiency virus type 1 proteome following primary infection. J Virol (2006) 2.48
The genotype of early-transmitting HIV gp120s promotes α (4) β(7)-reactivity, revealing α (4) β(7) +/CD4+ T cells as key targets in mucosal transmission. PLoS Pathog (2011) 2.32
Human immunodeficiency virus type 1 subtype distribution in the worldwide epidemic: pathogenetic and therapeutic implications. J Virol (2007) 2.32
HIV-1 group M conserved elements vaccine. PLoS Pathog (2007) 2.28
T-cell vaccine strategies for human immunodeficiency virus, the virus with a thousand faces. J Virol (2009) 2.17
Coping with viral diversity in HIV vaccine design. PLoS Comput Biol (2007) 2.01
Aiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidates. Expert Rev Vaccines (2006) 1.88
Recombinant HIV envelope proteins fail to engage germline versions of anti-CD4bs bNAbs. PLoS Pathog (2013) 1.85
A centralized gene-based HIV-1 vaccine elicits broad cross-clade cellular immune responses in rhesus monkeys. Proc Natl Acad Sci U S A (2008) 1.80
HIV-1 vaccine development after STEP. Annu Rev Med (2010) 1.64
Cross-subtype T-cell immune responses induced by a human immunodeficiency virus type 1 group m consensus env immunogen. J Virol (2006) 1.63
Enhancing exposure of HIV-1 neutralization epitopes through mutations in gp41. PLoS Med (2008) 1.60
Expanded breadth of the T-cell response to mosaic human immunodeficiency virus type 1 envelope DNA vaccination. J Virol (2008) 1.51
Antigenicity and immunogenicity of HIV-1 consensus subtype B envelope glycoproteins. Virology (2006) 1.51
Reconstruction and function of ancestral center-of-tree human immunodeficiency virus type 1 proteins. J Virol (2007) 1.46
Immunoinformatics comes of age. PLoS Comput Biol (2006) 1.35
Sequential immunization with a subtype B HIV-1 envelope quasispecies partially mimics the in vivo development of neutralizing antibodies. J Virol (2011) 1.33
Dynamic antibody specificities and virion concentrations in circulating immune complexes in acute to chronic HIV-1 infection. J Virol (2011) 1.28
Infectious virion capture by HIV-1 gp120-specific IgG from RV144 vaccinees. J Virol (2013) 1.26
Viral sequence diversity: challenges for AIDS vaccine designs. Expert Rev Vaccines (2008) 1.25
The effect of recombination on the reconstruction of ancestral sequences. Genetics (2010) 1.25
Binding interactions between soluble HIV envelope glycoproteins and quaternary-structure-specific monoclonal antibodies PG9 and PG16. J Virol (2011) 1.19
Mapping HIV-1 vaccine induced T-cell responses: bias towards less-conserved regions and potential impact on vaccine efficacy in the Step study. PLoS One (2011) 1.16
Siglecs facilitate HIV-1 infection of macrophages through adhesion with viral sialic acids. PLoS One (2011) 1.10
Importance of the V1/V2 loop region of simian-human immunodeficiency virus envelope glycoprotein gp120 in determining the strain specificity of the neutralizing antibody response. J Virol (2008) 1.09
HIV-1 p24(gag) derived conserved element DNA vaccine increases the breadth of immune response in mice. PLoS One (2013) 1.03
Altered response hierarchy and increased T-cell breadth upon HIV-1 conserved element DNA vaccination in macaques. PLoS One (2014) 0.99
HIV-1 vaccine immunogen design strategies. Virol J (2015) 0.98
Characterization of neutralizing antibody responses elicited by clade A envelope immunogens derived from early transmitted viruses. J Virol (2008) 0.96
Characterization of a putative ancestor of coxsackievirus B5. J Virol (2010) 0.96
Temporal analysis of HIV envelope sequence evolution and antibody escape in a subtype A-infected individual with a broad neutralizing antibody response. Virology (2010) 0.95
Co-immunization with multimeric scaffolds and DNA rapidly induces potent autologous HIV-1 neutralizing antibodies and CD8+ T cells. PLoS One (2012) 0.95
Neutralizing antibody escape during HIV-1 mother-to-child transmission involves conformational masking of distal epitopes in envelope. J Virol (2012) 0.93
Comparative immunogenicity of subtype a Human Immunodeficiency Virus type 1 envelope exhibiting differential exposure of conserved neutralization epitopes. J Virol (2009) 0.93
A cationic nanoemulsion for the delivery of next-generation RNA vaccines. Mol Ther (2014) 0.92
Engineering, expression, purification, and characterization of stable clade A/B recombinant soluble heterotrimeric gp140 proteins. J Virol (2011) 0.91
Stabilization of HIV-1 gp120-CD4 receptor complex through targeted interchain disulfide exchange. J Biol Chem (2010) 0.87
The role of amino acid changes in the human immunodeficiency virus type 1 transmembrane domain in antibody binding and neutralization. Virology (2011) 0.87
A directed molecular evolution approach to improved immunogenicity of the HIV-1 envelope glycoprotein. PLoS One (2011) 0.87
Envelope glycoprotein binding to the integrin α4β7 is not a general property of most HIV-1 strains. J Virol (2014) 0.86
Models of RNA virus evolution and their roles in vaccine design. Immunome Res (2010) 0.83
Achieving Potent Autologous Neutralizing Antibody Responses against Tier 2 HIV-1 Viruses by Strategic Selection of Envelope Immunogens. J Immunol (2016) 0.82
HIV-1 conserved elements p24CE DNA vaccine induces humoral immune responses with broad epitope recognition in macaques. PLoS One (2014) 0.82
Evaluation of heterologous vaginal SHIV SF162p4 infection following vaccination with a polyvalent Clade B virus-like particle vaccine. AIDS Res Hum Retroviruses (2012) 0.82
HIV DNA Vaccine: Stepwise Improvements Make a Difference. Vaccines (Basel) (2014) 0.81
Challenges in the design of a T cell vaccine in the context of HIV-1 diversity. Viruses (2014) 0.81
Progress on the induction of neutralizing antibodies against HIV type 1 (HIV-1). BioDrugs (2009) 0.80
An evaluation of phylogenetic methods for reconstructing transmitted HIV variants using longitudinal clonal HIV sequence data. J Virol (2014) 0.78
Genetic Consequences of Antiviral Therapy on HIV-1. Comput Math Methods Med (2015) 0.78
Protective efficacy of centralized and polyvalent envelope immunogens in an attenuated equine lentivirus vaccine. PLoS Pathog (2015) 0.78
Subtle evolutionary changes in the distribution of N-glycosylation sequons in the HIV-1 envelope glycoprotein 120. Int J Biol Sci (2010) 0.78
Adapting SHIVs In Vivo Selects for Envelope-Mediated Interferon-α Resistance. PLoS Pathog (2016) 0.76
Defining epitope coverage requirements for T cell-based HIV vaccines: theoretical considerations and practical applications. J Transl Med (2011) 0.76
DNA Immunization for HIV Vaccine Development. Vaccines (Basel) (2014) 0.75
DNA Prime-Boost Vaccine Regimen To Increase Breadth, Magnitude, and Cytotoxicity of the Cellular Immune Responses to Subdominant Gag Epitopes of Simian Immunodeficiency Virus and HIV. J Immunol (2016) 0.75
Ancestral Reconstruction. PLoS Comput Biol (2016) 0.75
Extracellular Matrix Proteins Mediate HIV-1 gp120 Interactions with α4β7. J Virol (2017) 0.75
CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res (1994) 392.47
MODELTEST: testing the model of DNA substitution. Bioinformatics (1998) 101.19
Antibody neutralization and escape by HIV-1. Nature (2003) 21.48
Seq-Gen: an application for the Monte Carlo simulation of DNA sequence evolution along phylogenetic trees. Comput Appl Biosci (1997) 17.32
Detection of replication-competent and pseudotyped human immunodeficiency virus with a sensitive cell line on the basis of activation of an integrated beta-galactosidase gene. J Virol (1992) 12.89
The antigenic structure of the HIV gp120 envelope glycoprotein. Nature (1998) 12.44
Consistent viral evolutionary changes associated with the progression of human immunodeficiency virus type 1 infection. J Virol (1999) 10.41
Diversity considerations in HIV-1 vaccine selection. Science (2002) 9.60
Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies. J Virol (2004) 8.99
Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection. N Engl J Med (1995) 8.23
Codon usage tabulated from international DNA sequence databases: status for the year 2000. Nucleic Acids Res (2000) 7.88
Human immunodeficiency virus type 1 viral protein R (Vpr) arrests cells in the G2 phase of the cell cycle by inhibiting p34cdc2 activity. J Virol (1995) 7.57
Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120. J Virol (2000) 6.71
The genetic data environment an expandable GUI for multiple sequence analysis. Comput Appl Biosci (1994) 5.68
A role for carbohydrates in immune evasion in AIDS. Nat Med (1998) 5.06
Improved coreceptor usage prediction and genotypic monitoring of R5-to-X4 transition by motif analysis of human immunodeficiency virus type 1 env V3 loop sequences. J Virol (2003) 4.56
DNA vaccines: protective immunizations by parenteral, mucosal, and gene-gun inoculations. Proc Natl Acad Sci U S A (1993) 4.49
Evolutionary and immunological implications of contemporary HIV-1 variation. Br Med Bull (2001) 4.41
Human immunodeficiency virus type 1 coreceptors participate in postentry stages in the virus replication cycle and function in simian immunodeficiency virus infection. J Virol (1997) 4.19
Neutralization of divergent HIV-1 isolates by conformation-dependent human antibodies to Gp120. Science (1991) 4.09
Tracking global patterns of N-linked glycosylation site variation in highly variable viral glycoproteins: HIV, SIV, and HCV envelopes and influenza hemagglutinin. Glycobiology (2004) 3.98
Antigenicity and immunogenicity of a synthetic human immunodeficiency virus type 1 group m consensus envelope glycoprotein. J Virol (2005) 2.89
Neutralization profiles of primary human immunodeficiency virus type 1 isolates in the context of coreceptor usage. J Virol (1998) 2.83
Autologous and heterologous neutralizing antibody responses following initial seroconversion in human immunodeficiency virus type 1-infected individuals. J Virol (1997) 2.75
Maintaining the integrity of human immunodeficiency virus sequence databases. J Virol (1996) 2.68
HIV type 1 variants transmitted to women in Kenya require the CCR5 coreceptor for entry, regardless of the genetic complexity of the infecting virus. AIDS Res Hum Retroviruses (2002) 2.68
Cloning of HTLV-4 and its relation to simian and human immunodeficiency viruses. Nature (1987) 2.61
Consensus and ancestral state HIV vaccines. Science (2003) 2.24
An improved plasmid DNA expression vector for direct injection into skeletal muscle. Hum Gene Ther (1996) 2.23
HIV sequence databases. AIDS Rev (2003) 2.20
Immunogenicity and protective efficacy of oligomeric human immunodeficiency virus type 1 gp140. J Virol (2001) 2.16
Native but not denatured recombinant human immunodeficiency virus type 1 gp120 generates broad-spectrum neutralizing antibodies in baboons. J Virol (1992) 1.94
Association of chemokine-mediated block to HIV entry with coreceptor internalization. J Biol Chem (2002) 1.79
Hyperglycosylated mutants of human immunodeficiency virus (HIV) type 1 monomeric gp120 as novel antigens for HIV vaccine design. J Virol (2003) 1.78
Refocusing neutralizing antibody response by targeted dampening of an immunodominant epitope. J Immunol (1997) 1.77
Clinical trials of HIV vaccines. Annu Rev Med (2002) 1.77
Analysis of the neutralizing antibody response elicited in rabbits by repeated inoculation with trimeric HIV-1 envelope glycoproteins. Virology (2005) 1.75
Multigene DNA priming-boosting vaccines protect macaques from acute CD4+-T-cell depletion after simian-human immunodeficiency virus SHIV89.6P mucosal challenge. J Virol (2003) 1.70
Role of N-linked glycans in a human immunodeficiency virus envelope glycoprotein: effects on protein function and the neutralizing antibody response. J Virol (2002) 1.69
Vaccination with HIV-1 gp120 DNA induces immune responses that are boosted by a recombinant gp120 protein subunit. Vaccine (1997) 1.63
Crosslinked HIV-1 envelope-CD4 receptor complexes elicit broadly cross-reactive neutralizing antibodies in rhesus macaques. Proc Natl Acad Sci U S A (2002) 1.55
Purification and characterization of oligomeric envelope glycoprotein from a primary R5 subtype B human immunodeficiency virus. J Virol (2002) 1.54
Augmentation of immune responses to HIV-1 and simian immunodeficiency virus DNA vaccines by IL-2/Ig plasmid administration in rhesus monkeys. Proc Natl Acad Sci U S A (2000) 1.50
Immunogenicity of DNA vaccines expressing human immunodeficiency virus type 1 envelope glycoprotein with and without deletions in the V1/2 and V3 regions. AIDS Res Hum Retroviruses (1998) 1.41
Localization of CD4+ T cell epitope hotspots to exposed strands of HIV envelope glycoprotein suggests structural influences on antigen processing. Proc Natl Acad Sci U S A (2001) 1.39
Safety and immunogenicity of combinations of recombinant subtype E and B human immunodeficiency virus type 1 envelope glycoprotein 120 vaccines in healthy Thai adults. J Infect Dis (2003) 1.33
Demographic factors that influence the neutralizing antibody response in recipients of recombinant HIV-1 gp120 vaccines. J Infect Dis (2004) 1.28
Centralized immunogens as a vaccine strategy to overcome HIV-1 diversity. Expert Rev Vaccines (2004) 1.23
HIV-1 diversity and vaccine development. Science (2002) 1.17
Evolution of a simian immunodeficiency virus pathogen. J Virol (1998) 1.15
Advancing AIDSVAX to phase 3. Safety, immunogenicity, and plans for phase 3. AIDS Res Hum Retroviruses (1998) 1.12
Immunogen sequence: the fourth tier of AIDS vaccine design. Expert Rev Vaccines (2004) 1.10
Past, present and future of HIV vaccine trials in developing countries. Vaccine (2002) 1.07
N-glycosylation of HIV-gp120 may constrain recognition by T lymphocytes. J Immunol (1991) 1.07
Requirement of diverse T-helper responses elicited by HIV vaccines: induction of highly targeted humoral and CTL responses. Expert Rev Vaccines (2004) 1.04
HIV vaccine development: lessons from the past and promise for the future. Curr HIV Res (2003) 1.03
HIV vaccine strategies. Vaccine (2002) 1.00
HIV-1 prophylactic vaccine trials in Thailand. Curr HIV Res (2005) 0.91
Predicting demographic group structures based on DNA sequence data. Mol Biol Evol (2003) 0.84
Acyclovir and transmission of HIV-1 from persons infected with HIV-1 and HSV-2. N Engl J Med (2010) 12.08
Two CD95 (APO-1/Fas) signaling pathways. EMBO J (1998) 10.42
Consistent viral evolutionary changes associated with the progression of human immunodeficiency virus type 1 infection. J Virol (1999) 10.41
Genetic relationships determined by a DNA heteroduplex mobility assay: analysis of HIV-1 env genes. Science (1993) 8.49
Site-specific integration by adeno-associated virus. Proc Natl Acad Sci U S A (1990) 7.06
HIV-1 nomenclature proposal. Science (2000) 6.61
Mass screening for lung cancer with mobile spiral computed tomography scanner. Lancet (1998) 6.09
Studies in subjects with long-term nonprogressive human immunodeficiency virus infection. N Engl J Med (1995) 5.69
Production of hepatitis B virus by a differentiated human hepatoma cell line after transfection with cloned circular HBV DNA. Cell (1986) 5.35
Photonic detection of bacterial pathogens in living hosts. Mol Microbiol (1995) 5.24
Relationship between pre-existing viral reservoirs and the re-emergence of plasma viremia after discontinuation of highly active anti-retroviral therapy. Nat Med (2000) 4.83
An effective AIDS vaccine based on live attenuated vesicular stomatitis virus recombinants. Cell (2001) 4.79
Cellular immune responses and viral diversity in individuals treated during acute and early HIV-1 infection. J Exp Med (2001) 4.42
Human immunodeficiency virus type 1 evolution in vivo tracked by DNA heteroduplex mobility assays. J Virol (1994) 4.35
Likelihood-based tests of topologies in phylogenetics. Syst Biol (2000) 4.34
P-selectin glycoprotein ligand-1 mediates rolling of human neutrophils on P-selectin. J Cell Biol (1995) 4.31
Neutralization of divergent HIV-1 isolates by conformation-dependent human antibodies to Gp120. Science (1991) 4.09
HIV quasispecies and resampling. Science (1996) 3.98
Adsorption of monovalent cations to bilayer membranes containing negative phospholipids. Biochemistry (1979) 3.88
Adsorption of divalent cations to bilayer membranes containing phosphatidylserine. J Gen Physiol (1981) 3.87
Vaccine protection by a triple deletion mutant of simian immunodeficiency virus. J Virol (1996) 3.84
The genome organization of STLV-3 is similar to that of the AIDS virus except for a truncated transmembrane protein. Cell (1987) 3.65
Binding of acylated peptides and fatty acids to phospholipid vesicles: pertinence to myristoylated proteins. Biochemistry (1993) 3.63
Sequence analysis and acute pathogenicity of molecularly cloned SIVSMM-PBj14. Nature (1990) 3.54
Regulation of apoptosis at cell division by p34cdc2 phosphorylation of survivin. Proc Natl Acad Sci U S A (2000) 3.44
Viral transduction of c-myc gene in naturally occurring feline leukaemias. Nature (1984) 3.39
Angiopoietin-1 inhibits endothelial cell apoptosis via the Akt/survivin pathway. J Biol Chem (2000) 3.30
Multidrug-resistant human immunodeficiency virus type 1 strains resulting from combination antiretroviral therapy. J Virol (1996) 3.21
Growth rate of small lung cancers detected on mass CT screening. Br J Radiol (2000) 3.18
Molecular epidemiology of HIV transmission in a dental practice. Science (1992) 3.10
SIV adaptation to human cells. Nature (1989) 3.09
Apoptotic cell death and tissue remodelling during mouse mammary gland involution. Development (1992) 3.04
Effect of intron A from human cytomegalovirus (Towne) immediate-early gene on heterologous expression in mammalian cells. Nucleic Acids Res (1991) 2.92
Large-scale monitoring of host cell gene expression during HIV-1 infection using cDNA microarrays. Virology (2000) 2.92
Quantitation of target molecules from polymerase chain reaction-based limiting dilution assays. AIDS Res Hum Retroviruses (1997) 2.91
Binding of small basic peptides to membranes containing acidic lipids: theoretical models and experimental results. Biophys J (1996) 2.89
Molecular cloning of a feline leukemia virus that induces fatal immunodeficiency disease in cats. Science (1988) 2.86
Lethal mutagenesis of HIV with mutagenic nucleoside analogs. Proc Natl Acad Sci U S A (1999) 2.85
Plasma viremia in macaques infected with simian immunodeficiency virus: plasma viral load early in infection predicts survival. J Virol (1997) 2.81
The role of electro-osmosis in the electric-field-induced movement of charged macromolecules on the surfaces of cells. Biophys J (1981) 2.81
Electrostatic interactions among hydrophobic ions in lipid bilayer membranes. Biophys J (1978) 2.80
Slower evolution of human immunodeficiency virus type 1 quasispecies during progression to AIDS. J Virol (1997) 2.72
Maintaining the integrity of human immunodeficiency virus sequence databases. J Virol (1996) 2.68
Strong sequence conservation among horizontally transmissible, minimally pathogenic feline leukemia viruses. J Virol (1988) 2.62
Cloning of HTLV-4 and its relation to simian and human immunodeficiency viruses. Nature (1987) 2.61
The LIM-only protein PINCH directly interacts with integrin-linked kinase and is recruited to integrin-rich sites in spreading cells. Mol Cell Biol (1999) 2.56
Increased DNA vaccine delivery and immunogenicity by electroporation in vivo. J Immunol (2000) 2.54
Disease-specific and tissue-specific production of unintegrated feline leukaemia virus variant DNA in feline AIDS. Nature (1986) 2.52
Antibodies to cell membrane antigens associated with human T-cell leukemia virus in patients with AIDS. Science (1983) 2.48
Results of three-year mass screening programme for lung cancer using mobile low-dose spiral computed tomography scanner. Br J Cancer (2001) 2.46
Nucleotide sequences of a feline leukemia virus subgroup A envelope gene and long terminal repeat and evidence for the recombinational origin of subgroup B viruses. J Virol (1986) 2.34
Binding of peptides with basic residues to membranes containing acidic phospholipids. Biophys J (1991) 2.30
Physician asthma management practices in Canada. Can Respir J (2001) 2.25
Nucleotide sequence of the envelope gene of Gardner-Arnstein feline leukemia virus B reveals unique sequence homologies with a murine mink cell focus-forming virus. J Virol (1983) 2.24
DNA sequence organization of the beta-globin complex in the BALB/c mouse. Cell (1980) 2.24
The adsorption of divalent cations to phosphatidylglycerol bilayer membranes. Biochim Biophys Acta (1981) 2.23
Expression and targeting of the apoptosis inhibitor, survivin, in human melanoma. J Invest Dermatol (1999) 2.21
Evolution of envelope sequences from the genital tract and peripheral blood of women infected with clade A human immunodeficiency virus type 1. J Virol (1998) 2.21
The role of fixed and mobile buffers in the kinetics of proton movement. Biochim Biophys Acta (1987) 2.18
Sequence arrangement and biological activity of cloned feline leukemia virus proviruses from a virus-productive human cell line. J Virol (1981) 2.17
Divergent patterns of progression to AIDS after infection from the same source: human immunodeficiency virus type 1 evolution and antiviral responses. J Virol (1997) 2.16
Binding of neomycin to phosphatidylinositol 4,5-bisphosphate (PIP2). Biochim Biophys Acta (1989) 2.13
The effector domain of myristoylated alanine-rich C kinase substrate binds strongly to phosphatidylinositol 4,5-bisphosphate. J Biol Chem (2000) 2.12
Protection against lethal simian immunodeficiency virus SIVsmmPBj14 disease by a recombinant Semliki Forest virus gp160 vaccine and by a gp120 subunit vaccine. J Virol (1996) 2.12
Amino-terminal basic residues of Src mediate membrane binding through electrostatic interaction with acidic phospholipids. Proc Natl Acad Sci U S A (1994) 2.12
Control of apoptosis during angiogenesis by survivin expression in endothelial cells. Am J Pathol (2000) 2.10
Characterization of a CD4-expressing macaque cell line that can detect virus after a single replication cycle and can be infected by diverse simian immunodeficiency virus isolates. Virology (1995) 2.08
Rapamycin inhibits cell motility by suppression of mTOR-mediated S6K1 and 4E-BP1 pathways. Oncogene (2006) 2.07
Translation of the diabetes nutrition recommendations for health care institutions: technical review. J Am Diet Assoc (1997) 2.06
Rates and patterns of chloroplast DNA evolution. Proc Natl Acad Sci U S A (1994) 2.06
Identification of human immunodeficiency virus type 1 envelope genes recombinant between subtypes B and F in two epidemiologically linked individuals from Brazil. J Virol (1994) 2.05
Coalescent estimates of HIV-1 generation time in vivo. Proc Natl Acad Sci U S A (1999) 2.02
The influence of granulocyte macrophage colony-stimulating factor and prior chemotherapy on the immunological response to a vaccine (ALVAC-CEA B7.1) in patients with metastatic carcinoma. Clin Cancer Res (2001) 2.01
Functional comparison of transactivation by simian immunodeficiency virus from rhesus macaques and human immunodeficiency virus type 1. J Virol (1988) 2.00
Human immunodeficiency virus type 1 populations in blood and semen. J Virol (1998) 1.99
Membrane binding of myristylated peptides corresponding to the NH2 terminus of Src. Biochemistry (1994) 1.99
Recombinant vaccine-induced protection against the highly pathogenic simian immunodeficiency virus SIV(mac251): dependence on route of challenge exposure. J Virol (1998) 1.98
Reprogramming of the tumour microenvironment by stromal PTEN-regulated miR-320. Nat Cell Biol (2011) 1.98
Genetic subtyping of human immunodeficiency virus using a heteroduplex mobility assay. PCR Methods Appl (1995) 1.96
Different subsets of enteric bacteria induce and perpetuate experimental colitis in rats and mice. Infect Immun (2001) 1.94
Transduction of endogenous envelope genes by feline leukaemia virus in vitro. Nature (1988) 1.94
Genetic analysis of HIV-1 isolates from Brazil reveals presence of two distinct genetic subtypes. AIDS Res Hum Retroviruses (1994) 1.90
Structured antiretroviral treatment interruptions in chronically HIV-1-infected subjects. Proc Natl Acad Sci U S A (2001) 1.89
The hereditary renal cell carcinoma 3;8 translocation fuses FHIT to a patched-related gene, TRC8. Proc Natl Acad Sci U S A (1998) 1.86
Molecular analysis and pathogenesis of the feline aplastic anemia retrovirus, feline leukemia virus C-Sarma. J Virol (1986) 1.84
The pleckstrin homology domain of phospholipase C-delta 1 binds with high affinity to phosphatidylinositol 4,5-bisphosphate in bilayer membranes. Biochemistry (1995) 1.84
Viral genetic determinants of T-cell killing and immunodeficiency disease induction by the feline leukemia virus FeLV-FAIDS. J Virol (1991) 1.83
Phosphoinositide-specific phospholipase C-delta 1 binds with high affinity to phospholipid vesicles containing phosphatidylinositol 4,5-bisphosphate. Biochemistry (1992) 1.82
Nck-2, a novel Src homology2/3-containing adaptor protein that interacts with the LIM-only protein PINCH and components of growth factor receptor kinase-signaling pathways. Mol Biol Cell (1998) 1.81
Phosphorylation, high ionic strength, and calmodulin reverse the binding of MARCKS to phospholipid vesicles. J Biol Chem (1994) 1.78
Electrostatics and the membrane association of Src: theory and experiment. Biochemistry (1998) 1.78
Electrostatic properties of membranes containing acidic lipids and adsorbed basic peptides: theory and experiment. Biophys J (1999) 1.77